Dr Karin Hellner
|Tel||+44 (0)1865 221019|
We are carrying out a number of research studies to help us design and test new treatments for cervical abnormalities caused by infection with oncogenic HPV that can lead to cancer.
HPV Vaccine Trial
REVEAL-01 is investigating the first therapeutic vaccine to show efficacy against cervical abnormalities associated with HPV-16 and HPV-18. Its predecessor trial was published in the Lancet in 2015, indicating the vaccine could present a non-surgical option to treat CIN2/3. REVEAL-01 is a randomised, double-blind, placebo-controlled study involving 200 sites worldwide.
HPV Immunity study
This trial aims to find out how the immune system clears high-risk HPV, the viruses that cause cervical cancer (http://www.jenner.ac.uk/hpvhttp://www.jenner.ac.uk/hpv). We are looking for women aged 16-24 years who are in good health. If you are interested, please contact the research team on firstname.lastname@example.org.
Senior Fellow in Women's Health
- Honorary Consultant Gynaecologist and Colposcopist at Oxford University Hospitals NHS Foundation Trust
- Clinical Lead for Colposcopy
- Lead for Cervical Sample Taker Register
- UK Chief Investigator and Oxford Principal Investigator for REVEAL-01 Trial
Biography & Research
I received my medical degree from the Humboldt-University of Berlin in 2003 and split my specialist training between the Charité - Universitätsmedizin Berlin, Germany, and Oxford University Hospitals NHS Trust, in the UK.
I interrupted my clinical training and spent 4 years as a postdoctoral research fellow at Harvard Medical School / Brigham & Women's Hospital in Boston, USA, where I have been working on the molecular mechanisms of human papillomavirus (HPV) associated carcinogenesis and drug discovery strategies for cervical cancer.
In 2011, I joined the University of Oxford as a Clinical Lecturer and am part of Prof. Zondervan's and Prof. Becker's Endometriosis Care and Research (EndoCaRe) team. My laboratory work focuses on transcriptomic profiling of healthy and diseased endometrium at the single-cell level.
I have a strong clinical interest in HPV associated cervical disease and am leading a research programme in the field of the molecular basis and clinical managment of cervical dysplasia. I am the clinical lead for the colposcopy service in Oxford and Principal Investigator of multiple national and international clinical trials.
In addition, I am a board member of the British Society for Colposcopy and Cervical Pathology (BSCCP) representing the South-East of England, a BSCCP accredited colposcopy trainer and elected member of the Society for Reproductive Investigation (SRI).
Recent advances in understanding and preventing human papillomavirus-related disease
Hellner K. and Dorrell L., (2017), F1000 Research
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.
Taylor C. et al, (2017), Oncotarget, 8, 17960 - 17980
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
Hellner K. et al, (2016), EBioMedicine
Evaluation Of the Monocyte To Lymphocyte Ratio As a Predictive Marker in Endometriosis Patients.
Hellner K. et al, (2016), REPRODUCTIVE SCIENCES, 23, 327A - 327A
Viral perturbations of host networks reflect disease etiology.
Gulbahce N. et al, (2012), PLoS Comput Biol, 8
Fellowships & Awards
- 2000 - 2001: PhD student fellowship by the Charite - Medical Faculty, Humboldt-University of Berlin
- 2007 - 2008: Postdoctoral Research Fellowship by the German Research Foundation (DFG) for basic research at Harvard Medical School Boston, USA
- 2010: DNA Tumor Virus Conference Grant
- 2010: Brigham & Women's Hospital Peer Mentor Award
- 2015: Oxford University Clinical Academic Graduate School (OUCAGS) Career Development Grant
- 2015: OUCAGS Travel Grant for Clinical Lecturers